Recent studies [46,47] have reported upregulation of PIK3-AKT signaling and alterations of the mTOR-NF2-AKT pathway in ESS, while inhibition of PI3K and mTOR has been shown to restrain growth in an ESS cell line [48]. This evidence concerns the gene AKT1 and endometrioid stromal sarcoma.